Brain Metastases from Prostate Cancer: An Emerging Clinical Problem with Implications for the Future Therapeutic Scenario

• Siegel R , WardE, BrawleyO, JemalA. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.CA Cancer J. Clin.61, 212–236 (2011).
   PubMed Web of Science ®Google Scholar
• Ferlay J , ParkinDM, Steliarova-FoucherE. Estimates of cancer incidence and mortality in Europe in 2008.Eur. J. Cancer46, 765–781 (2010).
   PubMed Web of Science ®Google Scholar
• Attar RM , TakimotoCH, GottardisMM. Castration-resistant prostate cancer: locking up the molecular escape routes.Clin. Cancer Res.15, 3251–3255 (2009).
   PubMed Web of Science ®Google Scholar
• Tannock IF , OsobaD, StocklerMRet al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J. Clin. Oncol. 14, 1756–1764 (1996).
   PubMed Web of Science ®Google Scholar
• Kantoff PW , HalabiS, ConawayMet al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J. Clin. Oncol. 17, 2506–2513 (1999).
   PubMed Web of Science ®Google Scholar
• Tannock IF , de WitR, BerryWRet al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351, 1502–1512 (2004).
   PubMed Web of Science ®Google Scholar
• Petrylak DP , TangenCM, HussainMHet al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351, 1513–1520 (2004).
   PubMed Web of Science ®Google Scholar
• de Bono JS , OudardS, OzgurogluMet al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147–1154 (2010).
   PubMed Web of Science ®Google Scholar
• de Bono JS , LogothetisCJ, MolinaAet al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).
   PubMed Web of Science ®Google Scholar
• Kantoff PW , HiganoCS, ShoreNDet al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411–422 (2010).
   PubMed Web of Science ®Google Scholar
• Scher HI , FizaziK, SaadFet al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367(13), 1187–1197 (2012).
   PubMed Web of Science ®Google Scholar
• Gavrilovic IT , PosnerJB. Brain metastases: epidemiology and pathophysiology.J. Neurooncol.75, 5–14 (2005).
   PubMed Web of Science ®Google Scholar
• Barnholtz-Sloan JS , SloanAE, DavisFG, VigneauFD, LaiP, SawayaRE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System.J. Clin. Oncol.22, 2865–2872 (2004).
   PubMed Web of Science ®Google Scholar
• Schouten LJ , RuttenJ, HuveneersHA, TwijnstraA. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma.Cancer94, 2698–2705 (2002).
   PubMed Web of Science ®Google Scholar
• Eichler AF , LoefflerJS. Multidisciplinary management of brain metastases.Oncologist12, 884–898 (2007).
   PubMed Web of Science ®Google Scholar
• Talmadge JE , FidlerIJ. AACR centennial series: the biology of cancer metastasis: historical perspective.Cancer Res.70, 5649–5669 (2010).
   PubMed Web of Science ®Google Scholar
• Paget S . The distribution of secondary growths in cancer of the breast.Lancet133, 571–573 (1889).
   Google Scholar
• Duda DG , DuyvermanAM, KohnoMet al. Malignant cells facilitate lung metastasis by bringing their own soil. Proc. Natl Acad. Sci. USA 107, 21677–21682 (2010).
   PubMed Web of Science ®Google Scholar
• Langley RR , FidlerIJ. The seed and soil hypothesis revisited – the role of tumor-stroma interactions in metastasis to different organs.Int. J. Cancer128, 2527–2535 (2011).
   PubMed Web of Science ®Google Scholar
• Biddle A , MackenzieIC. Cancer stem cells and EMT in carcinoma.Cancer Metastasis Rev.31, 285–293 (2012).
   Web of Science ®Google Scholar
• Chambers AF , GroomAC, MacDonaldIC. Dissemination and growth of cancer cells in metastatic sites.Nat. Rev. Cancer2, 563–572 (2002).
   PubMed Web of Science ®Google Scholar
• Tremont-Lukats IW , BobustucG, LagosGK, LolasK, KyritsisAP, PuduvalliVK. Brain metastasis from prostate carcinoma: the M.D. Anderson Cancer Center experience.Cancer98, 363–368 (2003).
   PubMed Web of Science ®Google Scholar
• Salvati M , FratiA, RussoNet al. Brain metastasis from prostate cancer. Report of 13 cases and critical analysis of the literature. J. Exp. Clin. Cancer Res. 24, 203–207 (2005).
   PubMed Web of Science ®Google Scholar
• Krammer MJ , TomasinoA, SchulDB, AstnerST, MeierMP, LumentaCB. Modern management of rare brain metastases in adults.J. Neurooncol.105, 9–25 (2011).
   PubMed Web of Science ®Google Scholar
• Hess KR , VaradhacharyGR, TaylorSHet al. Metastatic patterns in adenocarcinoma. Cancer 106, 1624–1633 (2006).
   PubMed Web of Science ®Google Scholar
• Long MA , HusbandJE. Features of unusual metastases from prostate cancer.Br. J. Radiol.72, 933–941 (1999).
   PubMed Web of Science ®Google Scholar
• Smedby KE , BrandtL, BacklundML, BlomqvistP. Brain metastases admissions in Sweden between 1987 and 2006.Br. J. Cancer101, 1919–1924 (2009).
   PubMed Web of Science ®Google Scholar
• McCutcheon IE , EngDY, LogothetisCJ. Brain metastasis from prostate carcinoma: antemortem recognition and outcome after treatment.Cancer86, 2301–2311 (1999).
   PubMed Web of Science ®Google Scholar
• Catane R , KaufmanJ, WestC, MerrinC, TsukadaY, MurphyGP. Brain metastasis from prostatic carcinoma.Cancer38, 2583–2587 (1976).
   PubMed Web of Science ®Google Scholar
• Taylor HG , LefkowitzM, SkoogSJ, MilesBJ, McLeodDG, CogginJT. Intracranial metastases in prostate cancer.Cancer53, 2728–2730 (1984).
   PubMed Web of Science ®Google Scholar
• Saitoh H , HidaM, ShimboT, NakamuraK, YamagataJ, SatohT. Metastatic patterns of prostatic cancer. Correlation between sites and number of organs involved.Cancer54, 3078–3084 (1984).
   PubMed Web of Science ®Google Scholar
• Caffo O , GernoneA, OrtegaCet al. Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era. J. Neurooncol. 107, 191–196 (2012).
   PubMed Web of Science ®Google Scholar
• Caffo O , VecciaA, FellinGet al. Frequency of brain metastases from prostate cancer: an 18-year single-institution experience. J. Neurooncol. doi: 10.1007/s11060-012-0994-1 (2012) (Epub ahead of print).
   Google Scholar
• Stone KR , MickeyDD, WunderliH, MickeyGH, PaulsonDF. Isolation of a human prostate carcinoma cell line (DU 145).Int. J. Cancer21, 274–281 (1978).
   PubMed Web of Science ®Google Scholar
• JuanYin J , TracyK, ZhangLet al. Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model. Clin. Exp. Metastasis 26, 403–414 (2009).
   PubMed Web of Science ®Google Scholar
• Yin JJ , ZhangL, MunasingheJ, LinnoilaRI, KellyK. Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer.Cancer Res.70, 8662–8673 (2010).
   PubMed Web of Science ®Google Scholar
• Thudi NK , ShuST, MartinCKet al. Development of a brain metastatic canine prostate cancer cell line. Prostate 71, 1251–1263 (2011).
   PubMed Web of Science ®Google Scholar
• Arnold SM , YoungAB, MunnRK, PatchellRA, NanayakkaraN, MarkesberyWR. Expression of p53, bcl-2, E-cadherin, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinases-1 in paired primary tumors and brain metastasis.Clin. Cancer Res.5, 4028–4033 (1999).
   PubMed Web of Science ®Google Scholar
• Lee TH , AvrahamHK, JiangS, AvrahamS. Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability.J. Biol. Chem.278, 5277–5284 (2003).
   PubMed Web of Science ®Google Scholar
• Narla G , DifeoA, FernandezYet al. KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. J. Clin. Invest. 118, 2711–2721 (2008).
   PubMed Web of Science ®Google Scholar
• Perrone G , VincenziB, ZagamiMet al. Reelin expression in human prostate cancer: a marker of tumor aggressiveness based on correlation with grade. Mod. Pathol. 20, 344–351 (2007).
   PubMed Web of Science ®Google Scholar
• Bendell JC , DomchekSM, BursteinHJet al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97, 2972–2977 (2003).
   PubMed Web of Science ®Google Scholar
• Duchnowska R , DziadziuszkoR, Czartoryska-ArlukowiczBet al. Risk factors for brain relapse in HER2-positive metastatic breast cancer patients. Breast Cancer Res. Treat. 117, 297–303 (2009).
   PubMed Web of Science ®Google Scholar
• Signoretti S , MontironiR, ManolaJet al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl Cancer Inst. 92, 1918–1925 (2000).
   PubMed Web of Science ®Google Scholar
• Neto AS , Tobias-MachadoM, WroclawskiMLet al. Her-2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis. J. Urol. 184, 842–850 (2010).
   PubMed Web of Science ®Google Scholar
• Domingo-Domenech J , FernandezPL, FilellaXet al. Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel. Ann. Oncol. 19, 269–275 (2008).
   PubMed Web of Science ®Google Scholar
• Tobiume M , YamadaY, NakamuraKet al. Significant prognostic factor of immunohistochemical HER-2 expression using initial prostate biopsy specimens with M1b prostate cancer. Prostate 71, 385–393 (2011).
   PubMed Web of Science ®Google Scholar
• Joos S , BergerheimUS, PanYet al. Mapping of chromosomal gains and losses in prostate cancer by comparative genomic hybridization. Genes Chromosomes Cancer 14, 267–276 (1995).
   PubMed Web of Science ®Google Scholar
• Wullich B , RiedingerS, BrinckUet al. Evidence for gains at 15q and 20q in brain metastases of prostate cancer. Cancer Genet. Cytogenet. 154, 119–123 (2004).
   PubMedGoogle Scholar
• Slamon DJ , Leyland-JonesB, ShakSet al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).
   PubMed Web of Science ®Google Scholar
• Kirsch DG , LedezmaCJ, MathewsCSet al. Survival after brain metastases from breast cancer in the trastuzumab era. J. Clin. Oncol. 23, 2114–2116 (2005).
   PubMed Web of Science ®Google Scholar
• Shao YY , LuLC, ChengAL, HsuCH. Increasing incidence of brain metastasis in patients with advanced hepatocellular carcinoma in the era of antiangiogenic targeted therapy.Oncologist16, 82–86 (2011).
   PubMed Web of Science ®Google Scholar
• Mongan JP , FadulCE, ColeBFet al. Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. Clin. Colorectal Cancer 8, 100–105 (2009).
   Web of Science ®Google Scholar
• Martel CL , GumerlockPH, MeyersFJ, LaraPN. Current strategies in the management of hormone refractory prostate cancer.Cancer Treat. Rev.29, 171–187 (2003).
   PubMed Web of Science ®Google Scholar
• Berthold DR , PondGR, SobanF, de WitR, EisenbergerM, TannockIF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.J. Clin. Oncol.26, 242–245 (2008).
   PubMed Web of Science ®Google Scholar
• Oudard S , BanuE, MedioniJet al. What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel? BJU Int. 103, 1641–1646 (2009).
   PubMed Web of Science ®Google Scholar
• Sartor AO , OudardS, OzgurogluMet al. Survival benefit from first docetaxel treatment for cabazitaxel plus prednisone compared with mitoxantrone plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in the TROPIC trial. J. Clin. Oncol. 29(Suppl.), Abstract 4525 (2011).
   Google Scholar
• Goodman O , ChiKN, MolinaAet al. Exploratory analysis of survival benefit and prior docetaxel (D) treatment in COU-AA-301, a Phase III study of abiraterone acetate (AA) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 30(Suppl. 5), Abstract 15 (2012).
   Web of Science ®Google Scholar
• Wolburg H , LippoldtA. Tight junctions of the blood–brain barrier: development, composition and regulation.Vascul. Pharmacol.38, 323–337 (2002).
   PubMed Web of Science ®Google Scholar
• Pozzilli C , BernardiS, MansiLet al. Quantitative assessment of blood–brain barrier permeability in multiple sclerosis using 68-Ga-EDTA and positron emission tomography. J. Neurol. Neurosurg. Psychiatry 51, 1058–1062 (1988).
   PubMed Web of Science ®Google Scholar
• Zhang RD , PriceJE, FujimakiT, BucanaCD, FidlerIJ. Differential permeability of the blood–brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice.Am. J. Pathol.141, 1115–1124 (1992).
   PubMed Web of Science ®Google Scholar
• Deeken JF , LoscherW. The blood–brain barrier and cancer: transporters, treatment, and Trojan horses.Clin. Cancer Res.13, 1663–1674 (2007).
   PubMed Web of Science ®Google Scholar
• Regina A , DemeuleM, LaplanteAet al. Multidrug resistance in brain tumors: roles of the blood–brain barrier. Cancer Metastasis Rev. 20, 13–25 (2001).
   PubMed Web of Science ®Google Scholar
• Genka S , DeutschJ, StahlePLet al. Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat. Cancer Chemother. Pharmacol. 27, 1–7 (1990).
   PubMed Web of Science ®Google Scholar
• Greig NH , SoncrantTT, ShettyHU, MommaS, SmithQR, RapoportSI. Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat.Cancer Chemother. Pharmacol.26, 263–268 (1990).
   PubMed Web of Science ®Google Scholar
• Romond EH , PerezEA, BryantJet al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673–1684 (2005).
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ , ProcterM, Leyland-JonesBet al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659–1672 (2005).
   PubMed Web of Science ®Google Scholar
• Lin NU , WinerEP. Brain metastases: the HER2 paradigm.Clin. Cancer Res.13, 1648–1655 (2007).
   PubMed Web of Science ®Google Scholar
• Stemmler HJ , SchmittM, WillemsA, BernhardH, HarbeckN, HeinemannV. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood–brain barrier.Anticancer Drugs18, 23–28 (2007).
   PubMed Web of Science ®Google Scholar
• Pestalozzi BC , BrignoliS. Trastuzumab in CSF.J. Clin. Oncol.18, 2349–2351 (2000).
   PubMed Web of Science ®Google Scholar
• Lin NU , BellonJR, WinerEP. CNS metastases in breast cancer.J. Clin. Oncol.22, 3608–3617 (2004).
   PubMed Web of Science ®Google Scholar
• Siena S , CrinoL, DanovaMet al. Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter Phase II study. Ann. Oncol. 21, 655–661 (2010).
   PubMed Web of Science ®Google Scholar
• Ekenel M , HormigoAM, PeakS, DeAngelisLM, AbreyLE. Capecitabine therapy of central nervous system metastases from breast cancer.J. Neurooncol.85, 223–227 (2007).
   PubMed Web of Science ®Google Scholar
• Lin NU , DierasV, PaulDet al. Multicenter Phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin. Cancer Res. 15, 1452–1459 (2009).
   PubMed Web of Science ®Google Scholar
• Sanson M , NapolitanoM, YayaRet al. Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a Phase II study. J. Neurooncol. 50, 245–249 (2000).
   PubMed Web of Science ®Google Scholar
• van der Veldt AA , HendrikseNH, SmitEFet al. Biodistribution and radiation dosimetry of 11C-labelled docetaxel in cancer patients. Eur. J. Nucl. Med. Mol. Imaging 37, 1950–1958 (2010).
   PubMed Web of Science ®Google Scholar
• Gerber DE , GrossmanSA, StreiffMB. Management of venous thromboembolism in patients with primary and metastatic brain tumors.J. Clin. Oncol.24, 1310–1318 (2006).
   PubMed Web of Science ®Google Scholar
• Klaassen Z , ShweikehF, ChamberlainR. Urological cancer metastasis to the brain: when should we resect?Uro. Today Int. J.5, article 10 (2012).
   Google Scholar
• van Brussel JP , MickischGH. Multidrug resistance in prostate cancer.Onkologie26, 175–181 (2003).
   PubMedGoogle Scholar
• Archimbaud Y , GiresP, PellerinR, NicheleG, PouletD. Pharmacokinetics of a new taxoid, 14C-TXD258, in blood, plasma and brain of the mouse, rat and dog.Proc. Am. Assoc. Cancer Res. Abstract 1375 (2000).
   Google Scholar
• Cisternino S , BourassetF, ArchimbaudY, SemiondD, SanderinkG, ScherrmannJM. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood–brain barrier in mice and rats.Br. J. Pharmacol.138, 1367–1375 (2003).
   PubMed Web of Science ®Google Scholar
• Dykes D , SarsatJ, BisseryMC. Efficacy evaluation of TXD258, a taxoid compound against orthotopic and subcutaneous glioblastomas.Proc. Am. Assoc. Cancer Res.41, 301 (2000).
   Google Scholar
• Ryan CJ , SmithMR, de BonoJSet al. Interim analysis (IA) results of COU-AA-302, a randomized, Phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 30(Suppl.), Abstract LBA4518 (2012).
   Google Scholar
• Foster WR , CarBD, ShiHet al. Drug safety is a barrier to the discovery and development of new androgen receptor antagonists. Prostate 71, 480–488 (2011).
   PubMed Web of Science ®Google Scholar
• Kelly WK , HalabiS, CarducciMet al. Randomized, double-blind, placebo-controlled Phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J. Clin. Oncol. 30, 1534–1540 (2012).
   PubMed Web of Science ®Google Scholar
• Demierre B , BerneyJ. Intracranial metastases of cancer of the prostate.Neurochirurgie29, 143–149 (1983).
   PubMed Web of Science ®Google Scholar
• Zhang X , TsukudaF, YamamotoN, TakenakaI. Brain metastasis from prostate cancer: a case report.Int. J. Urol.4, 519–521 (1997).
   PubMedGoogle Scholar
• Fervenza FC , WolanskyjAP, EklundHE, RichardsonRL. Brain metastasis: an unusual complication from prostatic adenocarcinoma.Mayo Clin. Proc.75, 79–82 (2000).
   PubMed Web of Science ®Google Scholar
• Behrens B , HusainMM, SchmidleyJW. Cystic solitary intracerebral metastasis from prostate adenocarcinoma.Neuroradiology43, 162–164 (2001).
   PubMed Web of Science ®Google Scholar
• Minami H , KanagawaK, WatanabeYet al. Complete remission of brain metastases from prostate cancer by γ knife radiosurgery: a case report. Hinyokika Kiyo 47, 333–336 (2001).
   PubMedGoogle Scholar
• Tsai V , KimS, ClatterbuckRE, EwendMG, OliviA. Cystic prostate metastases to the brain parenchyma: report of two cases and review of the literature.J. Neurooncol.51, 167–173 (2001).
   PubMed Web of Science ®Google Scholar
• Erasmus CE , VerhagenWI, WautersCA, van LindertEJ. Brain metastasis from prostate small cell carcinoma: not to be neglected.Can. J. Neurol. Sci.29, 375–377 (2002).
   PubMed Web of Science ®Google Scholar
• Saito EY , VianiGA, FerrignoRet al. Whole brain radiation therapy in management of brain metastasis: results and prognostic factors. Radiat. Oncol. 1, 20 (2006).
   PubMed Web of Science ®Google Scholar
• Chiang PH , LeeTC, HuangCC. Intracranial metastasis of prostate cancer: report of two cases.Chang Gung. Med. J.27, 770–776 (2004).
   PubMedGoogle Scholar
• Confavreux CB , CottonF, TebibJG. Advanced MRI could help to differentiate meningeal carcinomatosis with mass effect from cerebral metastasis in prostate cancer.Bull. Cancer93, E31–E35 (2006).
   PubMedGoogle Scholar
• Grenader T , ShavitL, LossosA, PizovG, WygodaM. Brain metastases: a rare initial presentation of prostate cancer.Int. Urol. Nephrol.39, 537–539 (2007).
   PubMed Web of Science ®Google Scholar
• Chitale S , WebbR, MacIverD, PeatD. Multifocal symptomatic intracerebral metastases as the first manifestation of prostatic carcinoma: a report and literature review.Int. Urol. Nephrol.40, 675–678 (2008).
   PubMed Web of Science ®Google Scholar
• Castro Gomez JE , AnidoHU, CarballoCAet al. Brain metastases from prostate adenocarcinoma. Clin. Transl. Oncol. 11, 63–64 (2009).
   PubMed Web of Science ®Google Scholar
• Sweets T , BrackenRB, GeislerEJ, WarnickR. Intracranial treatment for solitary prostatic adenocarcinoma brain metastasis is curative.Urology73, 681–689 (2009).
   Web of Science ®Google Scholar
• Roberts-Thomson R , RosenthalMA, GonzalesM, DrummondK. Brain metastases in hormone refractory prostate cancer: a changing natural history?Intern. Med. J.39, 205–206 (2009).
   PubMed Web of Science ®Google Scholar
• Gokoz Dogu G , OzkanM, KocyigitY, DurakA, ErO, AltinbaM. Intracranial metastasis from adenocarcinoma of prostate: case report.Türk Onkoloji Dergisi26, 174–177 (2011).
   Google Scholar

Websites

• ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D. http://clinicaltrials.gov/ct2/show/NCT00490139?term=NCT00490139&rank=1
   Google Scholar
• Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer (FIRSTANA). http://clinicaltrials.gov/ct2/show/NCT01308567?term=NCT01308567&rank=1
   Google Scholar
• EMA: Assessment report for Zytiga (abiraterone). www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002321/WC500112860.pdf
   Google Scholar
• A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer (PREVAIL). http://clinicaltrials.gov/ct2/show/NCT01212991?term=NCT01212991&rank=1
   Google Scholar